Loading quotes...

Forecast

The analysts' average price target is €17.04 (-36.32%). The median is €17.04 (-36.32%).

Buy	8
Hold	4
Sell	0

News Go to news feed

Schrödinger bets on AI agent Bunsen and raises contract value

Schrödinger is advancing its drug discovery with the AI agent Bunsen, which is being deployed widely at Bristol Myers Squibb. The annual contract value rose 27% to 29.6 million, underscoring growing commercial demand. The stock has jumped recently as early tools show potential to accelerate drug development. » More on finanzen.net
Schrödinger accelerates cloud migration and raises software outlook

Schrödinger reports rising demand for its physics-based drug discovery platform: annualized contract value rose 27% in Q2 and revenue in the first half increased 19%. The share of hosted software revenue reached 47%, exceeding the three-year target and indicating the cloud migration is progressing faster than expected. New product Bunsen is attracting particularly strong customer interest, with all 20 leading pharma companies among its customers. Schrödinger is targeting adjusted EBITDA break-even by 2028 and is using spin-offs, upfront payments and cost discipline to improve profitability. » More on de.investing.com
Schrödinger beats Q2 2026 forecasts and returns to profitability

Schrödinger reported an adjusted Q2 2026 EPS of $0.08 versus an expected -$0.49 and revenue of $58.9 million versus an estimated $48.08 million. Annual contract value (ACV) rose 27% to $29.6 million, and the hosted software model accounted for 47% of software revenue. The company raised its full-year guidance for the drug discovery business to $65–75 million after a $10 million milestone payment from Ajax. The stock rose after the results, and Schrödinger emphasized long-term growth potential from new products like Bunsen and Predictive Tox despite near-term margin pressure. » More on de.investing.com

Financials

In the last quarter, Schrödinger had revenue of €56.94m and net profit of -€33.29m

(EUR)	September 2026	YoY
Revenue	56.94m	23.00%
Gross profit	33.77m	41.35%
Net profit	-33.29m	19.14%
EBITDA	-31.87m	19.98%

Fundamentals

Metric	Value
Market capitalization	€1.93bn
Number of shares	74.81m
52-week high/low	€30.29 - €9.82
Dividends	No
Beta	1.65
P/E ratio	-36.42
PEG ratio	-0.38
P/B ratio	7.14
P/S ratio	7.99

Company profile

Schrödinger, Inc., together with its subsidiaries, provides physics-based software platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on selling its software for drug discovery in the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.